Results 181 to 190 of about 310,289 (342)
Objective Lupus nephritis (LN) management remains challenging, and novel noninvasive biomarkers are needed. This study quantified serum soluble mediators in the Accelerating Medicines Partnership (AMP) LN cohort to identify biomarkers of histological features and treatment response.
Andrea Fava +26 more
wiley +1 more source
The impact of positive lifestyle behaviors on direct healthcare cost savings for low back pain
Objective This study aimed to investigate the relationship between a previously purpose‐developed lifestyle behavior scale and healthcare cost savings related to low back pain (LBP). Methods This longitudinal study utilised data from the AUstralian Twin BACK (AUTBACK) study. LBP and lifestyle behavior measures were collected at baseline.
Ye Tian +8 more
wiley +1 more source
K. Herold +4 more
semanticscholar +1 more source
Objectives The objectives of this study were to evaluate the correlation and agreement between ultrasound and computed tomography (CT) in measuring ascending aorta diameter in patients with giant cell arteritis (GCA) and to investigate the development of new ascending aortic aneurysms in patients with newly diagnosed GCA. Methods To achieve the primary
Anne C Bull Haaversen +4 more
wiley +1 more source
The Challenges of Anesthetic Management in Patients with Heart Failure Undergoing Resection of a Giant Catecholamine-Secreting Pheochromocytoma: A Case Report [PDF]
A Fernandes +3 more
openalex +1 more source
Anesthetic Experience in Three Patiente with Hurler's Syndrome [PDF]
Jae Chull Kim, Jae Kyu Jeon
openalex +1 more source
Objective Ultrasound (US) has been proposed as a potential tool for assessing skin fibrosis in systemic sclerosis (SSc). However, a large‐scale comparison of US‐based assessment with histological markers of skin fibrosis has not been reported. We evaluated the US‐based skin assessments for their face validity (differentiation between involved SSc and ...
Ruhani Desai +12 more
wiley +1 more source
Introduction There are no Food and Drug Administration (FDA) approved therapies for Raynaud's phenomenon (RP) treatment in the United States (U.S.). Clinical trials have been challenged by study design. Important advances in RP patient reported outcome measures and mechanistic quantification allows RP‐related pain characterization.
Tracy M Frech +4 more
wiley +1 more source

